Obwohl er unzählige Auszeichnungen verdient, hat der spanische Wissenschaftler Dr. Mariano Barbacid Probleme damit, dass seine bahnbrechende Krebsforschung von JEMAND finanziert wird … 🤔 🤔
Obwohl er unzählige Auszeichnungen verdient, hat der spanische Wissenschaftler Dr. Mariano Barbacid Probleme damit, dass seine bahnbrechende Krebsforschung von JEMAND finanziert wird … 🤔 🤔
Dr. Mariano Barbacid. Keep saying his name and spreading the word of his amazing, life saving work.
flamboyantdebauchry on
why thou ?? keep hearing of him but why no support
IslamYaDongomedov on
What’s the. Devils Avocado here? Any mainstream reason hes not getting approval or do they not even cover this in media?
Exo-Proctologist on
A quick google search shows that his research *has* been funded to the tune of 11 million euros since 2018. His research has shown promising results in mice, but transitioning to human trials is often called the „valley of death“ amongst biomedical researchers because *a lot* of projects just never get the funding for this phase. It’s hard to track down a number, but it looks like this phase alone could cost *another* 30 million euros, on top of all the regulatory red tape.
Capitalism strikes again. Private investors care more about investment risk than they do about the outcome.
weordie on
No money in a cure
herniatedballs on
There’s no money in a cure…
Leave A Reply
Du musst angemeldet sein, um einen Kommentar abzugeben.
6 Kommentare
Dr. Mariano Barbacid. Keep saying his name and spreading the word of his amazing, life saving work.
why thou ?? keep hearing of him but why no support
What’s the. Devils Avocado here? Any mainstream reason hes not getting approval or do they not even cover this in media?
A quick google search shows that his research *has* been funded to the tune of 11 million euros since 2018. His research has shown promising results in mice, but transitioning to human trials is often called the „valley of death“ amongst biomedical researchers because *a lot* of projects just never get the funding for this phase. It’s hard to track down a number, but it looks like this phase alone could cost *another* 30 million euros, on top of all the regulatory red tape.
Capitalism strikes again. Private investors care more about investment risk than they do about the outcome.
No money in a cure
There’s no money in a cure…